Company Overview
Company Type: Public Company
Website: www.mydecine.com
Number of Employees: 3
Ticker: MYCO.F (OTCPK)
Year Founded: 2013


Business Description
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
6.9
EBITDA
(14.8)
Total Enterprise Value
12.4
TEV/EBITDA
NM
EBIT
(14.8)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(14.2)
Total Debt
5.3
Price/Tang BV
NM
Total Assets
1.0
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-03-2023

Key Professionals
Name
Title
Bartch, David Joshua
Co-Founder, CEO, President & Chairman of the Board
Michaels, Damon 
Co-Founder & COO
Roscow, Robert 
Co-Founder, Chief Scientific Officer & Director
Ross, John Charles
CFO & Corporate Secretary
Stein, Sanford M.
Chief Compliance Officer & General Counsel
Kervitsky, Morgan 
Director of Marketing
Jetly, Rakesh 
Chief Medical Officer
Rudolphie, Michel 
President of the European Operations
Cook, William 
Interim CEO & Technical Director of Mindleap Health Inc.

Key Board Members
Name
Title
Bartch, David Joshua
Co-Founder, CEO, President & Chairman of the Board
Roscow, Robert 
Co-Founder, Chief Scientific Officer & Director
Barnett, Rick 
Member of Medical, Scientific & Technology Advisory Board
Bradley, John 
Member of Medical, Scientific & Technology Advisory Board
Carhart-Harris, Robin 
Member of Medical, Scientific & Technology Advisory Board
Castro, Carl A.
Member of Medical, Scientific & Technology Advisory Board
Erritzoe, David 
Member of Medical, Scientific & Technology Advisory Board
Frewen, Paul 
Member of Medical, Scientific & Technology Advisory Board
Gomez-Escolar, Anton 
Member of Medical, Scientific & Technology Advisory Board
Hoyer, Denton 
Member of Medical, Scientific & Technology Advisory Board
Lanius, Ruth 
Member of Medical, Scientific & Technology Advisory Board
McFarlane, Sandy 
Member of Medical, Scientific & Technology Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
789 West Pender Street Suite 810 | Vancouver, BC | V6C 1H2 | Canada
Phone: 720-277-9879   

Current and Pending Investors
OpenSky Opportunities Fund Ltd., Pioneer Garage Limited, Roth Canada, ULC, Stifel Nicolaus Canada Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.12
Market Cap (mm)
5.6
Open
 0.12
Shares Out. (mm)
45.2
Previous Close
 0.12
Float %
98.7%
Change on Day
(0.03)
Shares Sold Short (mm)
0.0
Change % on Day
(19.9)%
Dividend Yield %
-
Day High/Low
 0.12/ 0.12
Diluted EPS Excl. Extra Items
(1.20)
52 wk High/Low
 0.90/ 0.11
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0011
Avg 3M Dly Vlm (mm)
0.0029
Beta 5Y
3.09


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
OTCPK:MYCO.F - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
NeuroPharm Inc.
NeuroPharm Inc., a healthcare company, engages in development of pharmaceutical and natural health products for mental wellness. The company was incorporated in 2020 and is based in Orl√©ans, Canada. NeuroPharm Inc. operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
Pharmaceuticals
-
-
-
Levee Street Holdings, LLC
Levee Street Holdings, LLC distributes CBD products. The company is based in USA.Levee Street Holdings, LLC operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
Distributors
-
-
-
Mydecine, LLC
Mydecine, LLC engages in cultivation, processing, research and development, and product development of compounds found in strains of mushroom and fungi. Mydecine, LLC was incorporated in 2020 and is based in Denver, Colorado. Mydecine, LLC operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
Pharmaceuticals
-
-
-
ReLyfe Brand, LLC
ReLyfe Brand, LLC manufactures and sells cannabidiol (CBD) based products. The company is based in Denver, Colorado. As of August 13, 2019, ReLyfe Brand, LLC operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
Pharmaceuticals
-
-
-
TeaLief Brand, LLC
TeaLief Brand, LLC produces cannabinoids infused teas. The company is based in Colorado. As of August 13, 2019, TeaLief Brand, LLC operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
Packaged Foods and Meats
-
-
-
Drink Fresh Water LLC
Drink Fresh Water LLC manufactures Cannabidiol infused beverage. The company is headquartered in Santa Ana, California. As of February 8, 2019, Drink Fresh Water LLC operates as a subsidiary ofMydecine Innovations Group Inc.

United States and Canada
Soft Drinks and Non-alcoholic Beverages
-
-
-
1175987 B.C. Ltd.
1175987 B.C. Ltd. is based in the United States. As of August 28, 2018, 1175987 B.C. Ltd. operates as a subsidiary of Mydecine Innovations Group Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-15-2023
Sep-19-2023
Public Offering
Target
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)


2.79
May-19-2023
May-29-2023
Public Offering
Target
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
OpenSky Opportunities Fund Ltd.

3.68
Apr-4-2023
-
Public Offering
Target
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
OpenSky Opportunities Fund Ltd.

3.72
Jan-17-2023
Jan-19-2023
Public Offering
Target
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)


3.74
Nov-25-2022
Nov-29-2022
Public Offering
Target
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)


3.30
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-19-2023
Follow-on Equity Offerings
Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.
Sep-15-2023
Follow-on Equity Offerings
Mydecine Innovations Group Inc. has filed a Follow-on Equity Offering in the amount of CAD 3.75 million.
Jul-21-2023
Executive/Board Changes - Other
Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary
Jul-04-2023
Special/Extraordinary Shareholders Meeting
Mydecine Innovations Group Inc., Special/Extraordinary Shareholders Meeting, Jul 04, 2023
May-30-2023
Follow-on Equity Offerings
Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

M&A Advisors
Mark V. Connolly, Attorney at Law, Purdy Law Professional Corporation


Advisors
Most Recent Auditor
B F Borgers CPA, PC
M&A Advisors
Mark V. Connolly, Attorney at Law, Purdy Law Professional Corporation
Private Placement Advisors
Canaccord Genuity Corp., Roth Canada, ULC, Stifel Nicolaus Canada Inc.
Public Offering Advisors
B F Borgers CPA, PC, Fish Purdy LLP, Miller Thomson LLP, MNP LLP, Shim & Associates LLP, Wildeboer Dellelce LLP


Most Recent Auditor
B F Borgers CPA PC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:46 AM
MYCO.F
Flow of Funds Report for Mydecine Innovations Group Inc - prepared by Wright Investors Service
Notes
66
Roth MKM
Piros, Elemer
Sep 19, 2022 03:57 PM
MYCO.F
MYCOF: Suspending Rating and Price Target
EPS Estimates*
4
Roth MKM
Piros, Elemer
Mar 01, 2022 07:52 AM
MYCO.F
MYCOF: Pre-IND Meeting with the FDA
EPS Estimates*
4
Roth MKM
Piros, Elemer
Feb 02, 2022 07:42 AM
MYCO.F
MYCOF: Ready to go Pivotal
EPS Estimates*
5
Capital Network by Proactive Investors
Stacey, Edward John
Dec 07, 2021 01:45 PM
MYCO.F
Mydecine - Mental health solutions advancing
Reports
5
Roth MKM
Piros, Elemer
Nov 16, 2021 02:02 PM
MYCO.F
MYCOF: 3Q21 Results
EPS Estimates*
5
Roth MKM
Piros, Elemer
Sep 23, 2021 10:03 PM
MYCO.F
MYCOF: MYCO-003 Patent Filed
EPS Estimates*
4
Roth MKM
Piros, Elemer
Sep 08, 2021 05:17 AM
MYCO.F
MYCOF: To Start Potentially Pivotal Smoking Cessation Trial
EPS Estimates*
5
Capital Network by Proactive Investors
Stacey, Edward John
Sep 07, 2021 01:07 AM
MYCO.F
Mydecine Innovations Group: Research program moving to the next level
Reports
5
Capital Network by Proactive Investors
Stacey, Edward John
Jun 30, 2021 08:06 AM
MYCO.F
Mydecine Innovations Group: Initiation report
Initiation of Coverage*
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Bartch, David Joshua

375,976

0.83

0.1

Apr-04-2023


Roscow M.A., Robert 

127,332

0.28

0.0

Apr-04-2023


Michaels, Damon 

90,883

0.20

0.0

May-08-2023


Stein, Sanford M.

6,367

0.01

0.0

Apr-13-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Bartch, David Joshua
375,976
976

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Michaels, Damon 
90,883
(50,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-15
MYCO Mydecine files prospectus supplement for offering
Canada StockWatch


Company Coverage
This company is not on any Coverage List.

Products
CBD Bottled Water, CBD Infused, Nano Amplified Alkaline Water, CBD Topicals and Gel Capsules, CBD Vaporizer Pens, CBD Vitamin Pack (Future), Psilocybin, Telehealth Application


Upcoming Events
Date/Time
Type
Nov-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
3:17 PM
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
170 KB
Sep-27-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
171 KB
Sep-20-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
Material Change Report
73 KB
Sep-20-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
171 KB
Sep-19-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
171 KB
Sep-15-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
Shelf Prospectus (NI 44-102)
418 KB
Sep-15-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
172 KB
Aug-30-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
126 KB
Aug-14-2023
Jun-30-2023
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
Interim Financial Statements
199 KB
Aug-14-2023
-
Mydecine Innovations Group Inc. (OTCPK:MYCO.F)
SEDAR
News Releases
213 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Michaels, Damon  (Co-Founder & COO)
May-08-2023
Common Shares
(50,000)
(16,598)
Open Market Disposition
(35.49)
Multiple
-
May-08-2023
Common Shares
(29,000)
(9,097)
Open Market Disposition
-
Exchange Announcement
-
May-08-2023
Common Shares
(500)
(167)
Open Market Disposition
-
Exchange Announcement
-
May-08-2023
Common Shares
(2,000)
(699)
Open Market Disposition
-
Exchange Announcement
-
May-08-2023
Common Shares
(5,000)
(1,774)
Open Market Disposition
-
Exchange Announcement
-
May-08-2023
Common Shares
(13,500)
(4,860)
Open Market Disposition
-
Exchange Announcement
Michaels, Damon  (Co-Founder & COO)
Mar-21-2022
Common Shares
51,000
0
Other Acquisition
56.74
Multiple
-
Mar-21-2022
Common Shares
38,882
0
Other Acquisition
-
Exchange Announcement
-
Mar-21-2022
Common Shares
12,118
0
Other Acquisition
-
Exchange Announcement
Heinzl, Todd  (Former Director)
Feb-03-2022
Common Shares
974
36,985
Other Acquisition
(100.00)
Multiple
Michaels, Damon  (Co-Founder & COO)
Nov-25-2021 - Mar-21-2022
Common Shares
(51,000)
0
Derivative Exercise and Sale
-
Multiple
-
Nov-25-2021
Common Shares
51,000
0
Derivative Exercise
-
Exchange Announcement
-
Mar-21-2022
Common Shares
(51,000)
0
Sale
-
Exchange Announcement
Ditto Jr., Larry Dean (Former Chief Financial Officer)
Nov-25-2021
Common Shares
15,585
-
Other Acquisition
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bartch, David Joshua
Co-Founder, CEO, President & Chairman of the Board
720-277-9879
-
jbartch@mydecineinc.com
Roscow, Robert 
Co-Founder, Chief Scientific Officer & Director
720-277-9879
-

Barnett, Rick 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Bradley, John 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Carhart-Harris, Robin 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Castro, Carl A.
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Erritzoe, David 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Frewen, Paul 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Gomez-Escolar, Anton 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Hoyer, Denton 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

Lanius, Ruth 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

McFarlane, Sandy 
Member of Medical, Scientific & Technology Advisory Board
720-277-9879
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bartch, David Joshua
Co-Founder, CEO, President & Chairman of the Board
720-277-9879
-
jbartch@mydecineinc.com
Michaels, Damon 
Co-Founder & COO
720-277-9879
-

Roscow, Robert 
Co-Founder, Chief Scientific Officer & Director
720-277-9879
-

Ross, John Charles
CFO & Corporate Secretary
(647) 291-4234
-
john@hempcocanada.com
Stein, Sanford M.
Chief Compliance Officer & General Counsel
720-277-9879
-

Kervitsky, Morgan 
Director of Marketing
(720) 689-4638
-

Jetly, Rakesh 
Chief Medical Officer
720-277-9879
-

Rudolphie, Michel 
President of the European Operations
720-277-9879
-

Cook, William 
Interim CEO & Technical Director of Mindleap Health Inc.
720-277-9879
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT‚ÄôS FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence‚Äôs opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
